These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21166708)

  • 41. Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma.
    Sentani K; Tashiro T; Oue N; Yasui W
    APMIS; 2007 Dec; 115(12):1422-5. PubMed ID: 18184414
    [No Abstract]   [Full Text] [Related]  

  • 42. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
    Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 45. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quality indicators for the care of breast cancer in vulnerable elders.
    Naeim A; Sawhney R; MacLean CH; Sanati H
    J Am Geriatr Soc; 2007 Oct; 55 Suppl 2():S258-69. PubMed ID: 17910546
    [No Abstract]   [Full Text] [Related]  

  • 49. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression.
    Altundag K; Tezcan ME; Ozen M; Karaahmet F; Bulut N
    Med Hypotheses; 2007; 68(1):235. PubMed ID: 16905272
    [No Abstract]   [Full Text] [Related]  

  • 51. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
    Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ
    Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human epidermal growth factor receptor 2 testing in breast cancer.
    Nielsen KV; Jørgensen JT; Schønau A; Oster A
    Arch Pathol Lab Med; 2007 Sep; 131(9):1330. PubMed ID: 17824784
    [No Abstract]   [Full Text] [Related]  

  • 53. The challenges of treating lobular carcinoma in situ.
    Visvanathan K
    Oncology (Williston Park); 2011 Oct; 25(11):1058, 1061, 1066. PubMed ID: 22106557
    [No Abstract]   [Full Text] [Related]  

  • 54. The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Kirova YM; Carroll S; Fourquet A; Offersen B; Aristei C; Chen JY
    Ann Oncol; 2018 Jan; 29(1):280-281. PubMed ID: 29045510
    [No Abstract]   [Full Text] [Related]  

  • 55. Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA.
    Mortimer JE; Shively JE
    J Nucl Med; 2019 Jan; 60(1):23-25. PubMed ID: 30573641
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A.
    Ramakrishna N; Anders CK; Temin S
    JCO Oncol Pract; 2022 Nov; 18(11):756-758. PubMed ID: 35947812
    [No Abstract]   [Full Text] [Related]  

  • 57. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.
    Giordano SH; Temin S; Davidson NE
    J Oncol Pract; 2018 Aug; 14(8):501-504. PubMed ID: 29989839
    [No Abstract]   [Full Text] [Related]  

  • 58. St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?
    Arnedos M; Gligorov J
    Ann Oncol; 2019 Oct; 30(10):1533-1535. PubMed ID: 31504122
    [No Abstract]   [Full Text] [Related]  

  • 59. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update Q and A.
    Crews JR; Kirshner JJ; Temin S
    JCO Oncol Pract; 2022 Nov; 18(11):753-755. PubMed ID: 35947811
    [No Abstract]   [Full Text] [Related]  

  • 60. [Interpretation of top issues of the 2013 St Gallen International Expert Consensus].
    Liu Y; Xu L; Xin L; Gao G
    Zhonghua Wai Ke Za Zhi; 2014 Jun; 52(6):401-4. PubMed ID: 25219552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.